These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 7796417

  • 1. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
    Brenner AJ, Aldaz CM.
    Cancer Res; 1995 Jul 01; 55(13):2892-5. PubMed ID: 7796417
    [Abstract] [Full Text] [Related]

  • 2. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK.
    Cancer Res; 1995 May 15; 55(10):2150-7. PubMed ID: 7743516
    [Abstract] [Full Text] [Related]

  • 3. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA.
    Cancer Res; 1995 Oct 15; 55(20):4531-5. PubMed ID: 7553622
    [Abstract] [Full Text] [Related]

  • 4. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
    Xu L, Sgroi D, Sterner CJ, Beauchamp RL, Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ, Louis DN.
    Cancer Res; 1994 Oct 15; 54(20):5262-4. PubMed ID: 7923151
    [Abstract] [Full Text] [Related]

  • 5. Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer.
    An HX, Niederacher D, Picard F, van Roeyen C, Bender HG, Beckmann MW.
    Genes Chromosomes Cancer; 1996 Sep 15; 17(1):14-20. PubMed ID: 8889502
    [Abstract] [Full Text] [Related]

  • 6. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A, Gaddipati JP, Moul JW, Srivastava S.
    J Urol; 1998 May 15; 159(5):1725-30. PubMed ID: 9554401
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ.
    Oncogene; 1995 Nov 02; 11(9):1843-51. PubMed ID: 7478613
    [Abstract] [Full Text] [Related]

  • 8. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN.
    Cancer Res; 1996 Jan 01; 56(1):150-3. PubMed ID: 8548755
    [Abstract] [Full Text] [Related]

  • 9. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L, Goodrow TL, Zhang SY, Klein-Szanto AJ, Chang H, Ruggeri BA.
    Cancer Res; 1996 Mar 01; 56(5):1137-41. PubMed ID: 8640773
    [Abstract] [Full Text] [Related]

  • 10. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K.
    Cancer Res; 1995 Jul 01; 55(13):2756-60. PubMed ID: 7796400
    [Abstract] [Full Text] [Related]

  • 11. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
    Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, Drabkin H, Gemmill R, Ahrent S, Sidransky D, Saccomanno G, Fountain JW, Anderson MW.
    Cancer Res; 1997 Jan 01; 57(1):1-6. PubMed ID: 8988029
    [Abstract] [Full Text] [Related]

  • 12. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Goodfellow PJ.
    Mol Carcinog; 1996 Jan 01; 15(1):5-10. PubMed ID: 8561866
    [Abstract] [Full Text] [Related]

  • 13. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
    Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ.
    Oncogene; 1996 Nov 07; 13(9):1867-73. PubMed ID: 8934532
    [Abstract] [Full Text] [Related]

  • 14. Increased p16 levels correlate with pRb alterations in human urothelial cells.
    Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C.
    Cancer Res; 1995 Feb 01; 55(3):493-7. PubMed ID: 7834615
    [Abstract] [Full Text] [Related]

  • 15. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
    Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR.
    Clin Cancer Res; 1995 Jul 01; 1(7):687-90. PubMed ID: 9816033
    [Abstract] [Full Text] [Related]

  • 16. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK.
    Oncogene; 1995 Mar 16; 10(6):1061-7. PubMed ID: 7700630
    [Abstract] [Full Text] [Related]

  • 17. p27/Kip1 mutation found in breast cancer.
    Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP.
    Cancer Res; 1996 May 15; 56(10):2400-4. PubMed ID: 8625318
    [Abstract] [Full Text] [Related]

  • 18. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM, Pearson JV, Hayward NK.
    Genes Chromosomes Cancer; 1996 Feb 15; 15(2):77-88. PubMed ID: 8834170
    [Abstract] [Full Text] [Related]

  • 19. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
    Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamoto K, Yokota J.
    Cancer Res; 1997 Mar 01; 57(5):907-12. PubMed ID: 9041193
    [Abstract] [Full Text] [Related]

  • 20. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
    Simoneau AR, Spruck CH, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA.
    Cancer Res; 1996 Nov 01; 56(21):5039-43. PubMed ID: 8895761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.